Actinic Keratosis Market, by Treatment (Medication, Surgical Procedure (Chemical peel Cryosurgery, Curettage and desiccation, laser surgery), Photodynamic Therapy, Combination Therapies (Cryosurgery and PDT, Cryosurgery and a topical treatment, Topical tr

Actinic Keratosis Market, by Treatment (Medication, Surgical Procedure (Chemical peel Cryosurgery, Curettage and desiccation, laser surgery), Photodynamic Therapy, Combination Therapies (Cryosurgery and PDT, Cryosurgery and a topical treatment, Topical treatments and PD), By End User (Hospitals and Specialty Clinics, Homecare), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Actinic Keratosis (AK) is the most common pre-cancer that forms on skin damaged by chronic exposure to ultraviolet (UV) rays from the sun. Actinic Keratosis is also known as solar keratosis. Actinic keratosis forms like a patch on the skin. The patches usually appear on areas of your body that are often exposed to the sun, such as your face, hands and arms, ears, scalp and legs. Sometimes actinic keratosis can turn into squamous cell skin cancer. For this reason, the lesions are often called pre-cancer. Patches are not life-threatening. But if patches are found and treated early, they do not have the chance to develop into skin cancer. Actinic Keratosis can affect:

• People with pale skin, blonde or red hair, and blue, green, or gray eyes
• People with darker skin, hair, and eyes who have been exposed to UV rays without protection
• Older adults
• People with suppressed immune systems (due to chemotherapy, AIDS, organ transplant, or other causes)
• People with rare conditions that make the skin very sensitive to UV rays, such as albinism or xeroderma pigmentosum (XP)

Market Dynamics

Increasing number of drug approvals for the treatment of actinic keratosis from regulatory bodies is expected to drive growth of the global actinic keratosis market during the forecast period. For instance, In November 2017, Perrigo Company plc, an Ireland based healthcare company, had announced that the company had received tentative approval from the U.S. Food and Drug Administration (FDA) for the generic version of Picato Gel (ingenol mebutate) 0.05%. It is indicated for the topical treatment of actinic keratosis.

High incidence rate of skin cancer is expected to drive growth of the global actinic keratosis market. For instance, according to American Academy of Dermatology Association 2022, Skin cancer is the most common cancer in the U.S. It is estimated that approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. It is estimated that the overall incidence of basal cell carcinoma (BCC) increased by 145% between 1976-1984 and between 2000-2010, and the overall incidence of squamous cell carcinoma (SCC) increased 263% over that same period.

Key features of the study:

• This report provides an in-depth analysis of global actinic keratosis market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global actinic keratosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals Inc., Biofrontera AG., Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global actinic keratosis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global actinic keratosis

Detailed Segmentation:

• Global Actinic Keratosis Market, By Treatment:
• Medication
• Surgical Procedure
• Chemical peel
• Cryosurgery
• Curettage and desiccation
• Laser surgery
• Photodynamic Therapy
• Combination Therapies
• Cryosurgery and PDT
• Cryosurgery and a topical treatment
• Topical treatments and PD
• Global Actinic Keratosis Market, By End User:
• Hospitals & Specialty Clinics
• Homecare
• Global Actinic Keratosis Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Almirall, S.A*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• Bausch Health Companies Inc.
• Perrigo Company plc
• Sun Pharmaceutical Industries Ltd.
• Hill Dermaceuticals, Inc.
• Spear Pharmaceuticals
• Tolmar Pharmaceuticals, Inc.
• Biofrontera AG
• Cipher Pharmaceuticals Inc.
• Vidac
• Athenex, Inc.
• 3M
• Mayne Pharma Group Limited

“*” marked represents similar segmentation in other categories in the respective section.